The currently established nomenclature for psychotropic drugs is outdated and no longer reflects the progress of neuroscience. In response to this situation, the Neuroscience-based Nomenclature (NbN) was developed: A system for the classification of psychotropic drugs, which brings important advantages for patients, clinicians, and researchers. The German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN) supports the introduction of the NbN in care, science, and teaching.